Trial Profile
A Phase II Study to Assess Efficacy of Pan-HER Inhibitor (HM781-36B, Poziotinib) in Stage IV Lung Adenocarcinoma With HER2 Mutation
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Dec 2016
At a glance
- Drugs Poziotinib (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Therapeutic Use
- Acronyms KASTT001
- 06 Dec 2016 New trial record